|
|
| Product Name: | ZL0420 | | Synonyms: | 2(1H)-Quinolinone, 6-[(1E)-2-(2-amino-4-hydroxy-5-methylphenyl)diazenyl]-3,4-dihydro-;6-[(1E)-2-(2-amino-4-hydroxy-5-methylphenyl)diazen-1-yl]-1,2,3,4-tetrahydroquinolin-2-one;(E)-ZL0420 | | CAS: | 2230496-80-5 | | MF: | C16H16N4O2 | | MW: | 296.32 | | EINECS: | | | Product Categories: | | | Mol File: | 2230496-80-5.mol |  |
| | ZL0420 Chemical Properties |
| Boiling point | 645.9±55.0 °C(Predicted) | | density | 1.41±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 30 mg/ml,DMSO: 30 mg/ml,DMSO:PBS (pH 7.2) (1:9): 0.1 mg/ml | | form | Solid | | pka | 9.56±0.36(Predicted) | | color | Yellow to orange |
| | ZL0420 Usage And Synthesis |
| Uses | ZL0420 is a potent and selective bromodomain-containing protein 4 (BRD4) inhibitor with IC50 values of 27 nM against BRD4 BD1 and 32 nM against BRD4 BD2. | | in vivo | ZL0420 demonstrates potent efficacy reducing airway inflammation in a mouse model with low toxicity. ZL0420 displays high efficacy and almost completely blocks the profound accumulation of neutrophils around the small and medium sized airways induced by poly(I:C) administration[1]. | | References | [1] Liu Z, et al. Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation. Eur J Med Chem. 2018 May 10;151:450-461. DOI:10.1016/j.ejmech.2018.04.006 |
| | ZL0420 Preparation Products And Raw materials |
|